Trefoil Factor 1 (TFF1, also named pS2), which serves as the gastrointestinal mucosal protector, is known as gastric-specific tumor suppressor gene. However, the genetic variants of TFF1 are still not well studied. In our study, we aim to explore the effects of tagging single nucleotide polymorphisms (tagSNPs) of TFF1 on risk and prognosis of gastric cancer. Seven tagSNPs of TFF1 gene were first analyzed in the discovery set, which was consisted of 753 cases and 950 cancer-free controls. Then, the validation set (940 cases and 1,042 controls) was used for further evaluation. Moreover, we also tested the relation between these tagSNPs and prognosis of gastric cancer (GC). A series of experiments were performed to investigate the underlying mechanisms. We found that rs3761376 AA in the promoter region of TFF1, could reduce the expression of TFF1 by affecting the binding affinity of estrogen receptor 1 (ESR1, ERa), and thereby increased the risk of GC (1.29, 1.08-1.53). Moreover, the rs3761376 AA genotype was also found associated with worse prognosis among patients receiving 5-FU based chemotherapy after surgery (1.71, 1.18-2.48). Further functional assays demonstrated that TFF1 could increase the chemosensitivity of 5-FU by modulating NF-jB targeted genes. These results identified the effect of rs3761376 on TFF1 expression, which accounted for the correlation with susceptibility and prognosis of GC; and this genetic variant may be a potential biomarker to predict the risk and survival of GC.
Introduction
Gastric cancer (GC) is a complex disease as a result of many factors such as Helicobacter pylori infection, dietary habits and genetic factors. 1, 2 According to the newest GLOBOCAN data, it is the fifth most common cancer and the third leading cause of the cancer-related death in the world with 951,000 new diagnosed cases and 723,000 deaths. 3 >70% of the GC cases worldwide occur in developing countries, and half of the global burden is found in Eastern Asia. In China, according to the epidemiological data, GC is the third major cancer with a high incidence rates (29.24 per 100,000) and ranks the third in cancer mortality. 4 The limited diagnostic capability and therapeutic options result in the poor prognosis with an overall 5-year survival rate around 30% worldwide. 5 The main obstacle is the very little understanding of the mechanisms underlying the GC development.
As known, the pathogenesis of GC is associated with precancerous lesions such as chronic atrophic gastritis. 6 Trefoil Factor 1 (TFF1, also named pS2), which is expressed to protect and repair the integrity of mucus layer, belongs to the trefoil factor family peptides that form a clover leaf-like domain through disulfide bonds and are resistant to proteolysis and the acidic environment. [7] [8] [9] TFF1 was first identified in the human breast cancer cell line MCF7, 10 and later was found located in the gastric epithelia and secreted mainly by the upper portion of the pit cells from body to the pyloric sphincter of the stomach.
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TFF1 was overexpressed in regenerating tissue after the mucosal injury, 12 and lost in about 60% of gastric tumors. 13, 14 Reduction of TFF1 was also observed in gastric adenomas compared to that in normal adjacent tissues. 15 The deficiency of TFF1 may result in the accumulation of undifferentiated gastric epithelial cells that could progress to the malignant cells. 16 According to the previous reports, TFF1 could reduce the cell proliferation by inducing the G1-S transition delay 17, 18 and loss of TFF1 may promote the gastric carcinogenesis cascade by activating the IKK/NF-jB pathway and PP2A-dependent bcatenin signaling. 19, 20 Therefore, TFF1 is considered as a gastric-specific tumor suppressor gene, which was also supported by the strong evidence provided by the tff1-knockout (Tff1-KO) mouse model. 16 The mechanisms of the repression of TFF1 have been studied. The silencing of TFF1 in GC can be explained by loss of heterozygosity (LOH) and promoter hypermethylation. 14, 21, 22 Histone modification such as H3K9 methylation and H3 deacetylation at the tff1 promoter can also induce the absence of tff1 in N-methyl-N-nitrosourea-induced GC mouse model. 21 Moreover, in transcriptional level, the role of CCAAT/enhancer binding protein-b and cofactor of BRCA1 in suppression of TFF1 has been affirmed 23, 24 . However, further investigations are still needed in the mechanisms regulating the TFF1 expression and its role in the gastric tumorigenesis.
Genetic alterations may also serve as an important participator in the occurrence of GC. Somatic variants of TFF1 gene are only identified in few gastric tumors. 14, 22 Therefore, the studies about the single nucleotide polymorphisms (SNPs), the most common sources of human genetic variations, should be put into our consideration. However, only two studies have reported the association between the TFF1 polymorphisms and GC risk. 25, 26 Compared to the single SNP analysis, the use of tagSNPs that could capture most of the common SNPs is considered more powerful.
In our study, we used the 1000 Genomes Project database for Chinese subjects to find out the tagSNPs located in the TFF1 gene and its promoter. Seven tagSNPs (i.e., rs35448902, rs225359, rs3761376, rs225358, rs13051704, rs2839488, and rs225355) were selected. Then, we used the large-scale twostage to evaluate the association of TFF1 genetic variants with the GC risk. As a result, we identified that TFF1 rs3761376 was associated with GC risk, and our further molecular biological experiment suggested that TFF1 rs3761376 AA could reduce the expression of TFF1 by affecting the binding affinity of estrogen receptor 1 (ESR1, ERa). Then, we also analyzed the role of rs3761376 on the prognosis of GC, and found this genetic variant was correlated with the survival of patients receiving 5-FU based postoperative chemotherapy, which can be explained by the function of TFF1 on chemosensitivity.
Material and Methods

Ethics statement
The study was approved by the institutional review board of Nanjing Medical University. Informed written consent was obtained from all subjects. The experimental protocol was carried out in accordance with the approved guidelines.
Study population
The present study contained two independent sets, that is, discovery and validation sets. 753 GC cases and 950 cancer-free participants were involved in the discovery set, and the validation set consisted of 1,022 cases and 1,065 cancer-free controls. All the subjects included in this two-stage study were periodical enrolled from the Cancer Clinical Research Base of Nanjing Medical University during March 2006 to January 2012 for the discovery set and January 1999 to December 2006 for the validation set. In the validation set, all the patients in the cases were conducted with follow-up studies. We excluded 78 patients (7.6%) without complete follow-up information and 4 patients (0.4%) with non-adenocarcinoma. Eventually, 940
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gastric adenocarcinoma patients were involved in this set. All the cases in our study were newly diagnosed with histopathologically identification. Patients with previous cancer and previous chemotherapy or radiotherapy were excluded. All the controls frequency-matched to cases by age and sex were recruited from people who were genetically unrelated to the cases. The clinical pathological data including age, sex, tumor site, depth of invasion, lymph node metastasis, distant metastasis and clinical TNM stage were collected from the medical records. According to Lauren's criteria, histopathology of tumor was divided into diffuse or intestinal types. 27 Depth of invasion, lymph nodes metastasis, distant metastasis, as well as clinical TNM stage, were recorded according to TNM classification (American Joint Commission on Cancer Staging; AJCCS, 6th).
SNP selection and genotyping
By using the Haploview 4.0 software (Cambridge, MA), tagSNPs capturing the common SNPs located in the full length of TFF1 gene and its 5 0 -flanking 2,000 bp region were selected based on UCSC browser (http://genome.ucsc.edu/). We selected the SNP sites based on the following criteria: (a) minor allele frequency (MAF) > 0.05 in the population of CHB (Han Chinese in Beijing, China) from the 1,000 Genomes Project; (b) r 2 > 0.8 analyzed based on pairwise linkage disequilibrium by Haploview 4.0. Finally, seven tagSNPs (i.e., rs35448902, rs225359, rs3761376, rs225358, rs13051704, rs2839488, and rs225355) were selected.
Genomic DNA was extracted from blood cell for the discovery set and controls of the validation set. In the cases of the validation set, paraffin sections of tissues were used for obtaining DNA. TaqMan SNP Genotyping Assay was performed to detect the genotypes of the tagSNPs by using ABI 7900HT real-time polymerase chain reaction (PCR) system (Applied Biosystems, Foster City, CA). Sequences of primers and probes of the tagSNPs are presented in Supplementary  Table S1 . 10% of the samples from both sets were randomly selected and re-genotyped for further confirmation, and the concordance rate was 100.0%. However, 23 of 1,065 controls failed in genotyping due to DNA quality. Eventually, the validation set were consisted of 940 cases and 1,042 controls.
Cell lines and cell culture
Two gastric cancer cell lines (SGC-7901 and MGC-803) were used in our study. All these cells were cultured in Roswell Park Memorial Institute 1640 medium with the addition of 10% fetal bovine serum, 100 U/ml penicillin, and 100 lg/ml streptomycin (Life Technologies/Gibco, Grand Island, NY) at 378C in a humidified atmosphere with 5% CO 2 .
Constructs of plasmids and transfection
In luciferase reporter plasmids, the sequences containing the 1,000-bp upstream fragment of the transcription start site of TFF1 with different alleles of rs3761376 were synthesized and constructed into pGL3-basic vector (Promega, Madison, WI).
The TFF1 overexpression vector was constructed by cloning the synthesized human TFF1 coding sequence into pcDNA3.1 expression vector (Promega, Madison, WI). All the plasmids were provided by Generay Company (Shanghai, China), and were confirmed by DNA sequencing. We also constructed the ESR1 siRNA (5 0 -GAGGGAGAATGTT-GAAACATT-3 0 ; GenePharma, Shanghai, China). The plasmid or siRNA was transfected into cells by Lipofectamine 2000 (Invtrogen, Carlsbad, CA).
Luciferase assay
Cells were transfected with the luciferase reporter plasmids containing the different allele of rs3761376. Meanwhile, E2 or ESR1 siRNA was also added. After 24 hr, the luciferase activity was detected on the Dual-Luciferase Reporter Assay System (Promega, Madison, WI). The expression was calculated by the ration of firefly luciferase to Renilla luciferase activities.
Electrophoretic mobility shift assay (EMSA)
Nuclear proteins were extracted from SGC-7901 and SGC-7901 with E2 or ESR1 siRNA. Synthetic double-stranded oligonucleotides for rs3761376 of TFF1 (probe G: 5 0 -TGCA AGGTCACGGTGGCCACCCC-3'; probe A: 5'-TGCAAGGT-CACGGTGGCTACCCC-3 0 ) were labeled with biotin. EMSA was performed by using the LightShift Chemiluminescent EMSA kit (Pierce, Rockford) according to the manufacturer's instructions. Briefly, nuclear proteins were incubated with biotin-labeled probes at room temperature for 30 min. For competition studies, unlabeled probes were added in nuclear extracts before the addition of labeled probes. After incubation, the DNA-protein complex was separated on 6.5% polyacrylamide gel, and then transferred to a nylon membrane. The signals were detected by stabilized streptavidinhorseradish peroxidase conjugate according to the procedures provided by the manufacturer.
Real-time PCR
We used Trizol Reagent (Invitrogen) to extract total RNA from cells and 60 pairs of patients' tumor tissues and adjacent normal tissues, which were included in 753 cases of the discovery set. The expression of mRNA was measured by real-time PCR (ABI 7300) with SYBR Green assay (TaKaRa Biotechnology, Dalian, China) after reverse transcription. The primers are provided as shown below. Each reaction was done in triplicate.
Western blotting
The performance of western blot assay was the same as previous study. 28 The following antibodies were used: TFF1
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Flow cytometry analysis
After transfected with TFF1 plasmids (or the empty plasmids as the control), the GC cells were incubated with 5-FU at indicated concentrations for 48 hr. The cells were harvested and resuspended in 500 ll binding buffer with the additions of Annexin V-FITC and 7-AAD (BioLegend, San Diego, CA). Then, the cells were incubated for 15 min at room temperature in the dark and subsequently analyzed by the flow cytometry.
Colony formation assay
The transfected cells were treated with 5-FU at various concentrations for 2 hr, and then trypsinized, seeded at a density of 2,000 cells per well in 6-well plates. After cultured for 2 weeks, the colonies were stained with crystal violet. The numbers of cloning were counted from three independent experiments.
Statistical analysis
Hardy-Weinberg equilibrium was tested using a goodness-offit v 2 test. Distribution differences of selected demographic characteristics were evaluated by Student's t test for continuous variables or Pearson's v 2 test for categorical variables.
The associations between TFF1 tagSNPs and GC risk were calculated by adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) from unconditional logistic regression analyses. Kaplan-Meier method and log-rank test were used to estimate the associations between overall survival and TFF1 polymorphism. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% CIs for predicting the effects of genotypes on GC survival. The Cox stepwise regression analysis was used to identify the independent predictive factors of GC prognosis, with p < 0.05 for entering and p > 0.10 for removal of the respective explanatory variables. Differences in luciferase activity, mRNA expression levels, number of colonies and cell apoptosis rate were tested by Student's t test. All statistical analyses were performed with the SAS 9.1 software (SAS Institute Inc., Cary, NC) and p < 0.05 for two-sided test was considered statistically significant.
Results
Characteristic of the study population
The distribution of the selected characteristics of the two sets is shown in Supplementary Table S2 . In total, our study included 1,693 cases and 1,992 controls with age (p 5 0.213) and gender (p 5 0.246) adequately matched. In the combined set, 656 patients were cardia cancer (38.7%) and 1,037 patients (61.3%) were noncardia cancer. More diffuse type tumors (22.3%) were observed than those with intestinal type (77.7%). The frequencies of depth of invasion were 16.6% (T1), 19.5% (T2), 54.6% (T3), and 9.3% (T4), respectively. Meanwhile, 60.4% of the patients were found with positive lymph node metastasis and 9.2% presented the distant metastasis. According to the clinical characteristics and based on the TNM classification of AJCC, 27.4% of patients were in stage I, 20.7% in stage II, 39.0% in stage III, and 12.9% in stage IV.
Association of TFF1 tagSNPs with GC risk
Genotype frequencies of the tagSNPs and their associations with GC risk are presented in Table 1 . The genotype distributions among the controls in two sets were all in accordance with Hardy-Weinberg equilibrium. In the discovery set, rs3761376 was observed associated with the increased GC risk in recessive model, and for rs2839488, a lower incidence of GC was displayed in the individuals carrying the G allele. For further confirmation, we evaluate the effects of these two tagSNPs in validation set. The association of rs2839488 with GC no longer existed. Nevertheless, the recessive model of rs3761376 was still consistently associated with GC risk, and the risk effect of rs3761376 was also found in the analyses of dominant and additive model. When GG genotype was used as the reference, the rs3761376 AA genotype was associated with the increased GC risk. Finally, in the combined set, only rs3761376 was found significantly increasing the GC risk in co-dominant, dominant, recessive and additive model. Because the recessive model of rs3761376 was correlated with the lower Akaike information criterion (AIC) and Bayesian Information (BIC) value, which indicated a better fit, than the dominant model (Supplementary Table S3 ), we performed the stratified analyses based on the recessive model. In the stratification of clinical characteristics, AA genotype exhibited higher incidence of GC than AG/GG genotype among subgroups of younger subjects (adjusted OR 5 1.38, 95% CI 5 1.10-1.72) and females (adjusted OR 5 1.60, 95% CI 5 1.15-2.22; Table 2 ). When stratified by clinical variables of GC, the risk effect of this polymorphism was more remarkable especially in patients with diffuse type (1.32, 1.08-1.61), negative lymph node metastasis (1.48, 1.18-1.85), negative distant metastasis (1.37, 1.11-1.69) and localized TNM stage (1.31, 1.10-1.56; Table 3 ). However, we did not find association between recessive model of rs3761376 and clinical features (Supplementary Table S4 ). 
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Association of rs3761376 with GC survival
We further analyzed the effect of rs3761376 on prognosis of GC patients. The characteristics and clinical variables of 940 GC patients were presented in Supplementary Table S7 ). Then, the stratification analysis of rs3761376 and GC survival was also performed among patients receiving adjuvant chemotherapy. As shown in Table 4 In order to estimate the main factors influencing the prognosis of patients receiving postoperative chemotherapy, a stepwise Cox regression analysis of selected characteristics, clinical features and rs3761376 was performed. Two variables (lymph node metastasis and rs3761376 in recessive model) were retained in the regression model (Supplementary Table  S8 ), indicating that rs3761376 might be an independent prognosis factor.
Potential effect of rs3761376 on regulation of TFF1
Because rs3761376 was located in the promoter of TFF1, this genetic variant might have potential functions via the regulation of the promoter activity by altering the binding of transcription factors. To identify which transcription factors might be influenced by rs3761376, bioinformatics analysis was performed by using RegulomeDB (http://regulome.stanford.edu) and HaploReg v4 (http://www.broadinstitute.org/mammals/haploreg). The results suggested that rs3761376 could change the motifs of specified transcription factors, especially estrogen receptor 1 (ESR1, ERa; Supplementary Tables S9 and S10), which was consistent with the fact that TFF1 was an estrogen-induced protein and this SNP site was located in the estrogen response element (ERE). 
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Effects of rs3761376 on transcriptional activity
To evaluate the influence of rs3761376 on promoter activity, we constructed different luciferase reporter vectors with either rs3761376 allele (G or A), which were transient transfected into SGC-7901 and MGC-803 cells. As the presented in Figure  1b , the vector carrying A allele exhibited the significantly reduced luciferase activity than that with G allele in both cells. This result was accordance with our previous observation of the association between reduced TFF1 expression and GC risk. Then, cells were activated by using E2 after transfection. Although the basic activity of both vectors increased after the stimulation, the remarkable lower activity was still found in the plasmid with A allele. However, after transfected with ESR1 siRNA, the different transcriptional activity between the two alleles was not obvious as before. These findings suggested that the A allele might reduce the promoter activity of TFF1 by altering the binding affinity of ESR1.
Effects of rs3761376 on nuclear protein-binding activity
To determine whether the two alleles have the different binding capacities for transcription factors, an EMSA was conducted with biotin-labeled probes containing either G or A allele and the nuclear extracts from SGC-7901 cells. We also synthesized the unlabeled probes as competitors. As shown in Figure 1c , the probe A formed fewer DNA-protein complexes than probe G (lane 3 vs. lane 4), which indicated the stronger binding of rs3761376 G allele. When the cells were activated by E2, both probes were able to bind more proteins. Similarly, compared to probe G, the probe A was observed exhibiting much weaker binding with nuclear proteins (lane 5 vs. lane 6). Moreover, when the expression of ESR1 was silenced by siRNA, the reduction of the DNA-protein complexes by either G or A allele was observed, and the difference of protein binding between the two probes was also attenuated (lane 7 vs. lane 8). Additionally, all the DNAprotein complexes were reduced by unlabeled probes in a dose dependent manner (Fig. 1d) , which validated the binding specificity. All these results were consistent with our previous findings of transcriptional activity, which further demonstrated the alternation of ESR1 binding to TFF1 promoter by rs3761376.
Correlation of rs3761376 genotypes with expression levels of TFF1
To further investigate the effects of rs3761376, we assessed the TFF1 expression in 60 tumor tissues and adjacent normal tissues from GC patients with known genotypes. Compared to GG genotype, a lower level of TFF1 expression was observed in AA genotype ( Fig. 1e and 1g) . But there was no significant difference of TFF1 expression between individuals with AG genotype and those with GG genotype. To further identify the biological significance of different models, we also analyzed the TFF1 expression levels in dominant and recessive model, respectively. As a result, in recessive model, AA genotype was associated with lower TFF1 expression than AG/GG genotypes ( Fig. 1f and 1h) . However, no significant difference was found in the dominant model.
Effects of TFF1 on 5-FU chemotherapy in GC
Based on the facts that the recessive model of rs3761376 could reduce the TFF1 expression and affect the survival of patients receiving adjuvant chemotherapy, we speculated that the different expression level of TFF1 might also influence the survival of the patients mentioned above. To validate this hypothesis, we evaluated the effects of TFF1 mRNA expression level on the prognosis of GC patients by using publicly available datasets (http://kmplot.com/analysis/index.php?p5 service&cancer5gastric). As shown in Figure 1 , higher TFF1 expression was associated with the better overall survival (OS) and progression-free (FP) survival of patients after 5-FU based adjuvant chemotherapy ( Fig. 1j and 1k) , which was consistent with our previous epidemiologic findings of the polymorphism (Fig. 1i) . It indicated that TFF1 might be associated with the 5-FU based chemotherapy sensitivity. Thus, we performed the CCK-8 assay to evaluate the viability of cells treated by 5-FU in a dose-dependent manner. Cells transfected with TFF1 plasmids exhibited better response to 5-FU than the controls (Fig. 2b and 2c) . Meanwhile, by conducting the Annexin V/7-AAD staining assay, we found a significant increase of cell apoptosis rate between the TFF1-expressing cells and the controls under the treatment of 5-FU, compared to those without the addition of 5-FU ( Fig. 2d and 2e) . Moreover, we performed the soft-agar colony formation assay to investigate the long-term effects of TFF1 on 5-FU-treated cells. The results revealed that there were significantly decreased numbers of colony formation in cells with higher TFF1 under the 5-FU treatment ( Fig. 2f and  2g ). All these results indicated the effects of TFF1 in cell death and proliferation. We first detected the apoptosis mediator, and TFF1 was observed correlated with the increased cleaved caspase 3 (Fig. 2h) . Previous study has reported the role of TFF1 in suppressing NF-jB pathway, which was regarded as a contributor to 5-FU chemoresistance. 30 Thus, we examined the NF-jB targeted proteins, and found that TFF1 significantly decreased the apoptosis-related proteins (such as Bcl-2, Bcl-xl) and the cell-cycle regulators (such as c-MYC and cyclin D1; Fig. 2h ).
Discussion
TFF1 is a well-known gastric-specific tumor suppressor gene, 11, 19, 20 which was found lost in more than half of gastric tumors due to epigenetic silencing, deletions of the TFF1 gene or dysregulation of transcription factors. 14, 21, 24 Accumulative evidences have demonstrated the effects of SNPs on the genes' expressions and functions, which in turn modulate the individual susceptibility of cancer. [31] [32] [33] However, the effects of TFF1 SNPs in human cancer have only been studied by two studies. 25 Thus, we have performed a two-stage case-control study to assess the association between TFF1 SNPs and GC risk. Finally, we identified that the TFF1 rs3761376 AA genotype significantly increased the GC risk. In stratified analyses, TFF1 rs3761376 presented a risk factor for GC in younger subjects (65 years) and females. Younger subjects with strong immune system and better health condition seemed to be more sensitive to genetic effects rather than environmental exposures. 34 The gender-specific difference might be due to the alteration of ER binding caused by this SNP site. We also observed TFF1 rs3761376 was correlated with increased GC risk among patients with negative lymph node metastasis, negative distant metastasis or localized TNM stage, which indicated the involvement of this variation in early stage of GC. TFF1 was reported associated with intestinal type of GC. 35 Although there was no statistical association between TFF1 rs3761376 and risk of intestinal GC, the potential risk effect was found. Therefore, further studies are still needed.
TFF1 is also a well-known protein regulated by ESR1 in breast cancer. Its promoter contains an imperfect ERRE (estrogen-related receptor a response element) and an imperfect ERE. 29, 36 TFF1 SNP rs3761376 was just located in the core motif of ERE. Polymorphisms in promoter region were reported having the ability to affect the transcription activity by altering the binding of transcription factors. 37, 38 Considering the imperfect ERE is associated with the weaker ER binding than the perfect one, any change of the nucleotide might make the binding affinity weaker. Thus, this genetic variant might influence the ER binding and regulate the TFF1 promoter activity. Consistent with our hypotheses, the results of bioinformatics analyses also suggested that rs3761376 A allele could attenuate the binding affinity of ER, especially the ESR1. In luciferase assay, the promoter activity was modulated by the expression of ESR1, and the A allele was found associated with reduced luciferase activity, when compared to the G allele. In EMSA assay, it displayed the similar results that the A allele decreased the binding affinity with ESR1. Moreover, by detecting the TFF1 expression from the tissues of GC patients with different genotypes of rs3761376, individuals carrying AA genotype were found with lower TFF1 expression than those carrying AG/GG genotypes. Taken the functional analyses together, it is plausible that TFF1 rs3761376 could alter the ESR1 binding and modulate the TFF1 expression, leading to the increased GC risk. These results were in accordance with our epidemiological findings.
At present, the prognosis of the GC patients remains poor with an overall 5-year survival rate around 30% worldwide, 5 although the GC mortality has significantly declined with the improvements in therapy during the past decades. Thus, finding new prognosis biomarkers, which can be easily extracted from blood or tissue samples, is very important. Recently, SNPs have been used to predict the clinical outcomes in order to guide the medical care and improve the patients' survival. 39 ,40 Therefore, we also evaluate the effect of rs3761376 on the prognosis of GC, and the follow-up study exhibited that the recessive model of this polymorphism could significant increased the risk of death among the patients receiving 5-FU based adjuvant chemotherapy. Based on the previous findings that rs3761376 AA genotype was associated with reduced TFF1 expression, it was reasonable to speculate that the expression of TFF1 could influence the chemosensitivity of 5-FU. And this hypothesis was confirmed by using the publicly available datasets, which displayed the association between poor survival and low TFF1 expression among the same group mentioned above. All these results indicated a putative function of TFF1 in chemosensitivity of 5-FU.
5-FU is widely used for the treatment of tumors including GC. 5-FU could affect on cell proliferation and apoptosis 41 through inhibition of DNA synthesis by targeting thymidylate synthase and direct incorporation of its metabolites into DNA and RNA, leading to the strand breaks 42 . Genes that could modulate cell growth and death have the potential to be the chemosensitizer of 5-FU. 43, 44 TFF1 was reported having the function in cell growth and death. [45] [46] [47] And in our functional studies, overexpression of TFF1 in gastric cancer cells enhanced the cytotoxicity of 5-FU by inhibiting proliferation and promoting apoptosis. NF-jB is the key regulatory signaling molecule responding to multiple stress stimuli, 48 which can be activated by 5-FU and thereby induce the chemoresistance 30, 49 through altering the expression of apoptosis-related proteins (such as Bcl-2, Bcl-xl) 50 and cellcycle regulators (such as c-MYC and cyclin D1). 51, 52 Inhibition of NF-jB activity has be used to increase the therapeutic efficacy of 5-FU. [53] [54] [55] Previous study has demonstrated the role of TFF1 in suppression of NF-jB pathway. 20 And in our study, our data also exhibited that TFF1 could modulate the expression of NF-jB pathway target genes, which indicated the sensitivity of 5-FU chemotherapy increased by TFF1 might be due to the suppression of NF-jB pathway. However, further validation is still needed to identify whether there exists TFF1-regulating NF-jB-independent pathways that sensitize the cancer cell to 5-FU. In summary, our results provided the first evidence that the TFF1 promoter activity reduced by rs3761376 A allele could account, at least partly, for the decreased TFF1 expression, which finally increased the risk of GC. And to the best of our knowledge, the present study is the first time to report the association between TFF1 polymorphism and the prognosis of GC patients receiving adjuvant chemotherapy and to analyze the function of TFF1 in 5-FU chemosensitivity. These findings suggested TFF1 rs3761376 may be used as a potential biomarker for GC diagnosis and prognosis.
